Sanofi and Selecta Biosciences, Inc. collaborate on new immunotherapy for celiac disease.
As part of a continued collaboration between Sanofi and Selecta Biosciences, Inc., an announcement was made last week that they have pursued an exclusive license to develop an antigen-specific immunotherapy for celiac disease. Selecta is eligible to receive significant financial backing for this new program in celiac disease. With positive outlooks on programs in immune tolerance currently being researched for the treatment of other conditions, this therapeutic option could put celiac disease patients one step closer to effectively managing their condition.
For more information about this collaborative research, visit the Selecta Biosciences, Inc. website.